The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

Blood

Volumn 124, Issue 5, 2014, Pages 720-728

  Murawski, Niels ^a   Held, Gerhard ^a   Ziepert, Marita ^b   Kempf, Barbara ^c   Viardot, Andreas ^d   Hänel, Mathias ^e   Witzens Harig, Mathias ^f   Mahlberg, Rolf ^g   Rübe, Christian ^a   Fleckenstein, Jochen ^a   Zwick, Carsten ^a   Glass, Bertram ^h   Schmitz, Norbert ^h   Zeynalova, Samira ^b   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Klinikum Landshut   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e KLINIKUM CHEMNITZ   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g TRIER UNIVERSITY   (Germany)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG DOSE INCREASE; EVENT FREE SURVIVAL; FEMALE; GERMANY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MULTIPLE CYCLE TREATMENT; NOSE CAVITY; ORBIT; OVERALL SURVIVAL; PARANASAL SINUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SALIVARY GLAND; SURVIVAL RATE; SURVIVAL TIME; TONGUE; TUMOR LOCALIZATION; TUMOR REGRESSION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FACIAL NEOPLASMS; FEMALE; GERMANY; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MIDDLE AGED; RADIOTHERAPY; SKULL NEOPLASMS; SURVIVAL RATE;

EID: 84905111740     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-535021     Document Type: Article

References (37)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
2. Pfreundschuh M, Trümper L, Osterborg A, et al; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
3. Pfreundschuh M, Schubert J, Ziepert M, et al German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
4. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. (Pubitemid 46638950)
5. Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118(17):4166-4172.
6. Weber AL, Rahemtullah A, Ferry JA. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. Neuroimaging Clin N Am. 2003;13(3):371-392. (Pubitemid 37025599)
7. Triantafillidou K, Dimitrakopoulos J, Iordanidis F, Gkagkalis A. Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: a clinical study of 58 cases and review of the literature. J Oral Maxillofac Surg. 2012;70(12):2776-2785.
8. Vega F, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. Ann Diagn Pathol. 2005;9(6):340-350. (Pubitemid 41676884)
9. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma. 2005;46(12):1721-1727. (Pubitemid 43203105)
10. Hausdorff J, Davis E, Long G, et al. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am. 1997;3(5):303-311.
11. Hart S, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW. Localised extranodal lymphoma of the head and neck: the Sheffield Lymphoma Group experience (1971-2000). Clin Oncol (R Coll Radiol). 2004;16(3):186-192. (Pubitemid 38559686)
12. Chen SW, Chang ST, Lu CL, et al. Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol. 2010;63(10):888-893.
13. Kojima M, Shimizu K, Nishikawa M, et al. Primary salivary gland lymphoma among Japanese: A clinicopathological study of 30 cases. Leuk Lymphoma. 2007;48(9):1793-1798. (Pubitemid 47386715)
14. Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol. 2003;26(1):6-11. (Pubitemid 36205889)
15. Pfreundschuh M, Trümper L, Kloess M, et al German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626-633. (Pubitemid 38970553)
16. Pfreundschuh M, Trümper L, Kloess M, et al German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634-641. (Pubitemid 38970554)
17. Trümper L, Zwick C, Ziepert M, et al German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol. 2008;19(3):538-544. (Pubitemid 351325677)
18. Pfreundschuh M, Zwick C, Zeynalova S, et al German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2008;19(3):545-552. (Pubitemid 351325678)
19. Glass B, Kloess M, Bentz M, et al German High-Grade Non-Hodgkin Lymphoma Study Group. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood. 2006;107(8):3058-3064.
20. Schmitz N, Kloess M, Reiser M, et al German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL). Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer. 2006;106(1):136-145. (Pubitemid 43032558)
21. Glass B, Ziepert M, Reiser M, et al German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol. 2010;21(11):2255-2261.
22. Zwick C, Hartmann F, Zeynalova S, et al German High-Grade Non-Hodgkin Lymphoma Study Group. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol. 2011;22(8):1872-1877.
23. Schmitz N, Nickelsen M, Ziepert M, et al German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250-1259.
24. de Leval L, Bonnet C, Copie-Bergman C, et al. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Ann Oncol. 2012;23(12):3143-3151.
25. Avilés A, Delgado S, Ruiz H, de la Torre A, Guzman R, Talavera A. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol. 1996;32B(1):19-23.
26. Qi SN, Li YX, Wang H, et al. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. Cancer. 2009;115(21):4980-4989.
27. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
28. Gutiérrez-García G, Colomo L, Villamor N, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010;51(7):1225-1232.
29. Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115-4122.
30. Cooper DL, Ginsberg SS. Brief chemotherapy, involved field radiation therapy, and central nervous system prophylaxis for paranasal sinus lymphoma. Cancer. 1992;69(12):2888-2893.
31. Yu JI, Nam H, Ahn YC, Kim WS, Park K, Kim SJ. Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys. 2010;78(2):507-512.
32. Chang DT, Amdur RJ, Pacholke H, et al. Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques? Am J Clin Oncol. 2009;32(2):145-149.
33. Mian M, Ferreri AJ, Rossi A, et al International Extranodal Lymphoma Study Group (Ielsg). Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline- containing chemotherapy. Leuk Lymphoma. 2013;54(1):62-68.
34. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-3902.
35. Ng AP, Wirth A, Seymour JF, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma. 2007;48(3):596-600. (Pubitemid 46487769)
36. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999;40(9):1407-1413. (Pubitemid 29428919)
37. Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Laryngoscope. 2010;120(5):937-944.